Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China

doi:10.4251/wjgo.v17.i5.102767

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (817)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

HTML

243

Figures (1-5)

Tables (1-2)

Sum=396

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

258

Sum=330

Publishing Process of This Article

Item

Count

Browse

Download

Sum=68

May 15, 2025 (publication date) through Jun 5, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. May 15, 2025; 17(5): 102767
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.102767

Full Size Figure Download Figure

Figure 5 The swimmer plot of patients treated with immunotherapy in microsatellite-stable cohort. Different colors represent the homologous recombination deficiency group and homologous recombination proficient group, respectively. The horizontal axis represents the survival time, each bar on the vertical axis represents a different patient, and symbols represent different clinical outcomes. HRD: Homologous recombination deficiency; HRP: Homologous recombination proficient.

Citation: Feng H, Zhao LY, Xu Z, Xie QF, Deng HJ, Yu J, Liu H. Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China. World J Gastrointest Oncol 2025; 17(5): 102767
URL: https://www.wjgnet.com/1948-5204/full/v17/i5/102767.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.102767